Suresh Ratnam
- Type
- Physician · Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology
- Where
- McAllen, TX
- NPI
- 1649217639
- Received
- $2,984,365 in 3,024 records, 2019 to 2025
- As principal investigator
- $329,819 of research payments to others in 78 records
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | General payment | 249 | $312,843 |
| 2024 | General payment | 345 | $490,675 |
| 2023 | General payment | 611 | $614,507 |
| 2022 | General payment | 564 | $504,058 |
| 2021 | General payment | 393 | $354,750 |
| 2020 | General payment | 250 | $218,257 |
| 2019 | General payment | 612 | $489,271 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 585 | $1,940,471 |
| Travel and Lodging | 1,393 | $564,020 |
| Honoraria | 57 | $222,448 |
| Consulting Fee | 80 | $124,595 |
| Compensation for serving as faculty or as a speaker for a medical education program | 25 | $80,685 |
| Food and Beverage | 870 | $51,546 |
| Education | 14 | $597 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-12-17 | JAZZ PHARMACEUTICALS INC. | $8,060 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ZEPZELCA Drug, HEMATOLOGY/ONCOLOGY | 2025 | |
| 2025-12-13 | JAZZ PHARMACEUTICALS INC. | $952 | Travel and Lodging | In-kind items and services | ZEPZELCA Drug, HEMATOLOGY/ONCOLOGY | 2025 | |
| 2025-12-12 | JAZZ PHARMACEUTICALS INC. | $214 | Travel and Lodging | In-kind items and services | ZEPZELCA Drug, HEMATOLOGY/ONCOLOGY | 2025 | |
| 2025-12-09 | AstraZeneca Pharmaceuticals LP | $738 | Travel and Lodging | In-kind items and services | LYNPARZA Drug, Oncology | 2025 | |
| 2025-12-09 | AstraZeneca Pharmaceuticals LP | $511 | Travel and Lodging | In-kind items and services | LYNPARZA Drug, Oncology | 2025 | |
| 2025-12-09 | AstraZeneca Pharmaceuticals LP | $112 | Food and Beverage | In-kind items and services | LYNPARZA Drug, Oncology | 2025 | |
| 2025-12-03 | JAZZ PHARMACEUTICALS INC. | $4,960 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ZEPZELCA Drug, HEMATOLOGY/ONCOLOGY | 2025 | |
| 2025-12-03 | Incyte Corporation | $1,569 | Travel and Lodging | Cash or cash equivalent | Jakafi Drug, Hematology/Oncology | 2025 | |
| 2025-12-02 | Pharmacosmos Therapeutics Inc. | $5,215 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | MONOFERRIC Drug, HEMATOLOGY | 2025 | |
| 2025-12-02 | AstraZeneca Pharmaceuticals LP | $124 | Food and Beverage | In-kind items and services | LYNPARZA Drug, Oncology | 2025 | |
| 2025-11-26 | AstraZeneca Pharmaceuticals LP | $5,360 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-11-25 | E.R. Squibb & Sons, L.L.C. | $10,920 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | OPDIVO Biological, Oncology | 2025 | |
| 2025-11-24 | Novartis Pharmaceuticals Corporation | $14 | Food and Beverage | In-kind items and services | KISQALI Drug, Oncology | 2025 | |
| 2025-11-22 | JAZZ PHARMACEUTICALS INC. | $923 | Travel and Lodging | In-kind items and services | ZEPZELCA Drug, HEMATOLOGY/ONCOLOGY | 2025 | |
| 2025-11-22 | JAZZ PHARMACEUTICALS INC. | $559 | Travel and Lodging | In-kind items and services | ZEPZELCA Drug, HEMATOLOGY/ONCOLOGY | 2025 | |
| 2025-11-21 | JAZZ PHARMACEUTICALS INC. | $99 | Food and Beverage | In-kind items and services | ZEPZELCA Drug, HEMATOLOGY/ONCOLOGY | 2025 | |
| 2025-11-20 | JAZZ PHARMACEUTICALS INC. | $968 | Travel and Lodging | In-kind items and services | ZEPZELCA Drug, HEMATOLOGY/ONCOLOGY | 2025 | |
| 2025-11-19 | JAZZ PHARMACEUTICALS INC. | $8,060 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ZEPZELCA Drug, HEMATOLOGY/ONCOLOGY | 2025 | |
| 2025-11-19 | Galvanize Therapeutics, Inc | $91 | Food and Beverage | In-kind items and services | ALIYA SYSTEM Device, PULSED ELECTRIC FIELD | 2025 | |
| 2025-11-18 | Karyopharm Therapeutics Inc. | $8,050 | Honoraria | Cash or cash equivalent | XPOVIO Drug, Oncology | 2025 | |
| 2025-11-18 | Pharmacosmos Therapeutics Inc. | $1,921 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | MONOFERRIC Drug, HEMATOLOGY | 2025 | |
| 2025-11-18 | Karyopharm Therapeutics Inc. | $753 | Travel and Lodging | In-kind items and services | XPOVIO Drug, Oncology | 2025 | |
| 2025-11-18 | Karyopharm Therapeutics Inc. | $658 | Travel and Lodging | In-kind items and services | XPOVIO Drug, Oncology | 2025 | |
| 2025-11-18 | Karyopharm Therapeutics Inc. | $343 | Travel and Lodging | In-kind items and services | XPOVIO Drug, Oncology | 2025 | |
| 2025-11-13 | AstraZeneca Pharmaceuticals LP | $124 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-11-10 | JAZZ PHARMACEUTICALS INC. | $712 | Travel and Lodging | In-kind items and services | ZEPZELCA Drug, HEMATOLOGY/ONCOLOGY | 2025 | |
| 2025-11-10 | JAZZ PHARMACEUTICALS INC. | $182 | Travel and Lodging | In-kind items and services | ZEPZELCA Drug, HEMATOLOGY/ONCOLOGY | 2025 | |
| 2025-11-08 | JAZZ PHARMACEUTICALS INC. | $137 | Travel and Lodging | In-kind items and services | ZEPZELCA Drug, HEMATOLOGY/ONCOLOGY | 2025 | |
| 2025-11-07 | AstraZeneca Pharmaceuticals LP | $1,340 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | LYNPARZA Drug, Oncology | 2025 | |
| 2025-11-07 | JAZZ PHARMACEUTICALS INC. | $102 | Food and Beverage | In-kind items and services | ZEPZELCA Drug, HEMATOLOGY/ONCOLOGY | 2025 | |
| 2025-11-03 | JAZZ PHARMACEUTICALS INC. | $10,540 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ZEPZELCA Drug, HEMATOLOGY/ONCOLOGY | 2025 | |
| 2025-10-30 | E.R. Squibb & Sons, L.L.C. | $1,096 | Travel and Lodging | Cash or cash equivalent | OPDIVO Biological, Oncology | 2025 | |
| 2025-10-30 | E.R. Squibb & Sons, L.L.C. | $682 | Travel and Lodging | Cash or cash equivalent | OPDIVO Biological, Oncology | 2025 | |
| 2025-10-30 | E.R. Squibb & Sons, L.L.C. | $201 | Travel and Lodging | Cash or cash equivalent | OPDIVO Biological, Oncology | 2025 | |
| 2025-10-30 | E.R. Squibb & Sons, L.L.C. | $87 | Food and Beverage | Cash or cash equivalent | OPDIVO Biological, Oncology | 2025 | |
| 2025-10-29 | JAZZ PHARMACEUTICALS INC. | $4,960 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ZEPZELCA Drug, HEMATOLOGY/ONCOLOGY | 2025 | |
| 2025-10-29 | Janssen Biotech, Inc. | $79 | Food and Beverage | In-kind items and services | RYBREVANT Drug, Oncology | 2025 | |
| 2025-10-24 | JAZZ PHARMACEUTICALS INC. | $199 | Travel and Lodging | In-kind items and services | ZEPZELCA Drug, HEMATOLOGY/ONCOLOGY | 2025 | |
| 2025-10-24 | JAZZ PHARMACEUTICALS INC. | $199 | Travel and Lodging | In-kind items and services | ZEPZELCA Drug, HEMATOLOGY/ONCOLOGY | 2025 | |
| 2025-10-24 | Genentech USA, Inc. | $31 | Food and Beverage | In-kind items and services | Itovebi Biological, BioOncology | 2025 | |
| 2025-10-23 | JAZZ PHARMACEUTICALS INC. | $105 | Travel and Lodging | In-kind items and services | ZEPZELCA Drug, HEMATOLOGY/ONCOLOGY | 2025 | |
| 2025-10-23 | JAZZ PHARMACEUTICALS INC. | $105 | Travel and Lodging | In-kind items and services | ZEPZELCA Drug, HEMATOLOGY/ONCOLOGY | 2025 | |
| 2025-10-23 | JAZZ PHARMACEUTICALS INC. | $72 | Food and Beverage | In-kind items and services | ZEPZELCA Drug, HEMATOLOGY/ONCOLOGY | 2025 | |
| 2025-10-22 | JAZZ PHARMACEUTICALS INC. | $132 | Food and Beverage | In-kind items and services | ZEPZELCA Drug, HEMATOLOGY/ONCOLOGY | 2025 | |
| 2025-10-21 | Incyte Corporation | $5,480 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Jakafi Drug, Hematology/Oncology | 2025 | |
| 2025-10-17 | Pharmacosmos Therapeutics Inc. | $488 | Travel and Lodging | In-kind items and services | MONOFERRIC Drug, HEMATOLOGY | 2025 | |
| 2025-10-16 | Pharmacosmos Therapeutics Inc. | $5,215 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | MONOFERRIC Drug, HEMATOLOGY | 2025 | |
| 2025-10-15 | AstraZeneca Pharmaceuticals LP | $250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | CALQUENCE Drug, Oncology | 2025 | |
| 2025-10-14 | Incyte Corporation | $927 | Travel and Lodging | Cash or cash equivalent | Jakafi Drug, Hematology/Oncology | 2025 | |
| 2025-10-14 | Incyte Corporation | $286 | Travel and Lodging | Cash or cash equivalent | Jakafi Drug, Hematology/Oncology | 2025 | |
| 2025-10-12 | JAZZ PHARMACEUTICALS INC. | $59 | Travel and Lodging | In-kind items and services | ZEPZELCA Drug, HEMATOLOGY/ONCOLOGY | 2025 | |
| 2025-10-12 | JAZZ PHARMACEUTICALS INC. | $59 | Travel and Lodging | In-kind items and services | ZEPZELCA Drug, HEMATOLOGY/ONCOLOGY | 2025 | |
| 2025-10-08 | AstraZeneca Pharmaceuticals LP | $6,030 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | LYNPARZA Drug, Oncology | 2025 | |
| 2025-10-08 | Rigel Pharmaceuticals, Inc. | $1,755 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | TAVALISSE Drug, Hematology | 2025 | |
| 2025-10-06 | ARRAY BIOPHARMA INC | $23 | Food and Beverage | In-kind items and services | XALKORI Drug, ONCOLOGY | 2025 | |
| 2025-10-02 | GlaxoSmithKline, LLC. | $119 | Food and Beverage | In-kind items and services | OJJAARA Drug, ONCOLOGY | 2025 | |
| 2025-10-01 | JAZZ PHARMACEUTICALS INC. | $428 | Travel and Lodging | In-kind items and services | ZEPZELCA Drug, HEMATOLOGY/ONCOLOGY | 2025 | |
| 2025-10-01 | Pharmacosmos Therapeutics Inc. | $360 | Travel and Lodging | In-kind items and services | MONOFERRIC Drug, HEMATOLOGY | 2025 | |
| 2025-10-01 | Pharmacosmos Therapeutics Inc. | $256 | Travel and Lodging | In-kind items and services | MONOFERRIC Drug, HEMATOLOGY | 2025 | |
| 2025-10-01 | Pharmacosmos Therapeutics Inc. | $248 | Travel and Lodging | In-kind items and services | MONOFERRIC Drug, HEMATOLOGY | 2025 | |
| 2025-10-01 | Pharmacosmos Therapeutics Inc. | $80 | Travel and Lodging | In-kind items and services | MONOFERRIC Drug, HEMATOLOGY | 2025 | |
| 2025-09-17 | AstraZeneca Pharmaceuticals LP | $672 | Travel and Lodging | In-kind items and services | LYNPARZA Drug, Oncology | 2025 | |
| 2025-09-17 | AstraZeneca Pharmaceuticals LP | $196 | Travel and Lodging | In-kind items and services | LYNPARZA Drug, Oncology | 2025 | |
| 2025-09-17 | AstraZeneca Pharmaceuticals LP | $102 | Food and Beverage | In-kind items and services | LYNPARZA Drug, Oncology | 2025 | |
| 2025-09-16 | AstraZeneca Pharmaceuticals LP | $6,030 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-09-11 | JAZZ PHARMACEUTICALS INC. | $1,040 | Travel and Lodging | In-kind items and services | ZEPZELCA Drug, HEMATOLOGY/ONCOLOGY | 2025 | |
| 2025-09-11 | JAZZ PHARMACEUTICALS INC. | $620 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ZEPZELCA Drug, HEMATOLOGY/ONCOLOGY | 2025 | |
| 2025-09-10 | Incyte Corporation | $5,480 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Jakafi Drug, Hematology/Oncology | 2025 | |
| 2025-09-10 | Incyte Corporation | $5,480 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Jakafi Drug, Hematology/Oncology | 2025 | |
| 2025-09-10 | AstraZeneca Pharmaceuticals LP | $805 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-09-10 | JAZZ PHARMACEUTICALS INC. | $749 | Travel and Lodging | In-kind items and services | ZEPZELCA Drug, HEMATOLOGY/ONCOLOGY | 2025 | |
| 2025-09-10 | AstraZeneca Pharmaceuticals LP | $562 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-09-10 | AstraZeneca Pharmaceuticals LP | $466 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-09-10 | AstraZeneca Pharmaceuticals LP | $119 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-09-05 | Pharmacosmos Therapeutics Inc. | $137 | Travel and Lodging | In-kind items and services | MONOFERRIC Drug, HEMATOLOGY | 2025 | |
| 2025-09-04 | Pharmacosmos Therapeutics Inc. | $103 | Food and Beverage | In-kind items and services | MONOFERRIC Drug, HEMATOLOGY | 2025 | |
| 2025-09-02 | Gilead Sciences, Inc. | $22 | Food and Beverage | In-kind items and services | Trodelvy Drug, ONC | 2025 | |
| 2025-08-28 | Incyte Corporation | $516 | Travel and Lodging | Cash or cash equivalent | Jakafi Drug, Hematology/Oncology | 2025 | |
| 2025-08-28 | Incyte Corporation | $515 | Travel and Lodging | Cash or cash equivalent | Jakafi Drug, Hematology/Oncology | 2025 | |
| 2025-08-28 | Incyte Corporation | $304 | Travel and Lodging | Cash or cash equivalent | Jakafi Drug, Hematology/Oncology | 2025 | |
| 2025-08-28 | Incyte Corporation | $125 | Food and Beverage | Cash or cash equivalent | Jakafi Drug, Hematology/Oncology | 2025 | |
| 2025-08-26 | Incyte Corporation | $927 | Travel and Lodging | Cash or cash equivalent | Jakafi Drug, Hematology/Oncology | 2025 | |
| 2025-08-26 | Incyte Corporation | $240 | Travel and Lodging | Cash or cash equivalent | Jakafi Drug, Hematology/Oncology | 2025 | |
| 2025-08-22 | Pharmacosmos Therapeutics Inc. | $667 | Travel and Lodging | In-kind items and services | MONOFERRIC Drug, HEMATOLOGY | 2025 | |
| 2025-08-22 | Pharmacosmos Therapeutics Inc. | $80 | Travel and Lodging | In-kind items and services | MONOFERRIC Drug, HEMATOLOGY | 2025 | |
| 2025-08-14 | Celgene Corporation | $30 | Food and Beverage | Cash or cash equivalent | REBLOZYL Biological, Hematology | 2025 | |
| 2025-08-07 | Rigel Pharmaceuticals, Inc. | $5,148 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | TAVALISSE Drug, Hematology | 2025 | |
| 2025-08-07 | Incyte Corporation | $736 | Travel and Lodging | Cash or cash equivalent | Jakafi Drug, Hematology/Oncology | 2025 | |
| 2025-08-06 | Astellas Pharma US Inc | $25 | Food and Beverage | In-kind items and services | Vyloy Drug, Oncology | 2025 | |
| 2025-07-30 | ABBVIE INC. | $31 | Food and Beverage | In-kind items and services | VENCLEXTA Drug, ONCOLOGY | 2025 | |
| 2025-07-29 | Novartis Pharmaceuticals Corporation | $24 | Food and Beverage | In-kind items and services | Fabhalta Drug, Immunology | 2025 | |
| 2025-07-28 | Daiichi Sankyo Inc. | $20 | Food and Beverage | In-kind items and services | Enhertu Drug, ONCOLOGY | 2025 | |
| 2025-07-24 | Exelixis Inc. | $4,620 | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | CABOMETYX Drug, Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | 2025 | |
| 2025-07-24 | Karyopharm Therapeutics Inc. | $4,025 | Honoraria | Cash or cash equivalent | XPOVIO Drug, Oncology | 2025 | |
| 2025-07-24 | AstraZeneca Pharmaceuticals LP | $1,340 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | LYNPARZA Drug, Oncology | 2025 | |
| 2025-07-23 | Rigel Pharmaceuticals, Inc. | $776 | Travel and Lodging | In-kind items and services | TAVALISSE Drug, Hematology | 2025 | |
| 2025-07-23 | Rigel Pharmaceuticals, Inc. | $286 | Travel and Lodging | In-kind items and services | TAVALISSE Drug, Hematology | 2025 | |
| 2025-07-23 | Rigel Pharmaceuticals, Inc. | $124 | Food and Beverage | In-kind items and services | TAVALISSE Drug, Hematology | 2025 | |
| 2025-07-23 | PFIZER INC. | $21 | Food and Beverage | In-kind items and services | IBRANCE Drug, ONCOLOGY | 2025 | |
| 2025-07-21 | E.R. Squibb & Sons, L.L.C. | $455 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-07-21 | E.R. Squibb & Sons, L.L.C. | $455 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-07-17 | GlaxoSmithKline, LLC. | $19 | Food and Beverage | In-kind items and services | OJJAARA Drug, ONCOLOGY | 2025 | |
| 2025-07-16 | Celgene Corporation | $17 | Food and Beverage | Cash or cash equivalent | REBLOZYL Biological, Hematology | 2025 | |
| 2025-07-15 | PUMA BIOTECHNOLOGY, INC. | $17 | Food and Beverage | In-kind items and services | NERLYNX Drug, ONCOLOGY | 2025 | |
| 2025-07-14 | Exelixis Inc. | $641 | Travel and Lodging | In-kind items and services | CABOMETYX Drug, Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | 2025 | |
| 2025-07-10 | Exelixis Inc. | $330 | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | CABOMETYX Drug, Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | 2025 | |
| 2025-07-08 | Exelixis Inc. | $70 | Travel and Lodging | In-kind items and services | CABOMETYX Drug, Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | 2025 | |
| 2025-07-08 | Exelixis Inc. | $70 | Travel and Lodging | In-kind items and services | CABOMETYX Drug, Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | 2025 | |
| 2025-07-08 | Exelixis Inc. | $70 | Travel and Lodging | In-kind items and services | CABOMETYX Drug, Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | 2025 | |
| 2025-07-03 | Incyte Corporation | $7,535 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Jakafi Drug, Hematology/Oncology | 2025 | |
| 2025-07-03 | AstraZeneca Pharmaceuticals LP | $4,020 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | LYNPARZA Drug, Oncology | 2025 | |
| 2025-07-02 | E.R. Squibb & Sons, L.L.C. | $455 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-07-02 | E.R. Squibb & Sons, L.L.C. | $455 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-07-02 | Syndax Pharmaceuticals, Inc. | $22 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-07-01 | Incyte Corporation | $5,480 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Jakafi Drug, Hematology/Oncology | 2025 | |
| 2025-07-01 | Exelixis Inc. | $20 | Food and Beverage | Cash or cash equivalent | CABOMETYX Drug, Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | 2025 | |
| 2025-06-26 | PFIZER INC. | $30 | Education | In-kind items and services | IBRANCE Drug, ONCOLOGY | 2025 | |
| 2025-06-26 | Eisai Inc. | $24 | Food and Beverage | In-kind items and services | Lenvima Drug, Oncology | 2025 | |
| 2025-06-25 | Daiichi Sankyo Inc. | $670 | Consulting Fee | Cash or cash equivalent | Enhertu Drug, ONCOLOGY | 2025 | |
| 2025-06-24 | Incyte Corporation | $2,740 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Jakafi Drug, Hematology/Oncology | 2025 | |
| 2025-06-24 | Incyte Corporation | $813 | Travel and Lodging | Cash or cash equivalent | Jakafi Drug, Hematology/Oncology | 2025 | |
| 2025-06-24 | Incyte Corporation | $356 | Travel and Lodging | Cash or cash equivalent | Jakafi Drug, Hematology/Oncology | 2025 | |
| 2025-06-23 | E.R. Squibb & Sons, L.L.C. | $455 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-06-23 | E.R. Squibb & Sons, L.L.C. | $455 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-06-19 | Genentech USA, Inc. | $25 | Food and Beverage | In-kind items and services | Tecentriq Biological, BioOncology | 2025 | |
| 2025-06-18 | AstraZeneca Pharmaceuticals LP | $250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-06-17 | Incyte Corporation | $618 | Travel and Lodging | Cash or cash equivalent | Jakafi Drug, Hematology/Oncology | 2025 | |
| 2025-06-17 | Novartis Pharmaceuticals Corporation | $20 | Food and Beverage | In-kind items and services | SCEMBLIX Drug, Oncology | 2025 | |
| 2025-06-16 | Exelixis Inc. | $1,980 | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | CABOMETYX Drug, Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | 2025 | |
| 2025-06-12 | Incyte Corporation | $266 | Travel and Lodging | Cash or cash equivalent | Jakafi Drug, Hematology/Oncology | 2025 | |
| 2025-06-11 | Incyte Corporation | $6,850 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Jakafi Drug, Hematology/Oncology | 2025 | |
| 2025-06-11 | AstraZeneca Pharmaceuticals LP | $5,360 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | DATROWAY Biological, Oncology | 2025 | |
| 2025-06-10 | Exelixis Inc. | $70 | Travel and Lodging | In-kind items and services | CABOMETYX Drug, Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | 2025 | |
| 2025-06-10 | Exelixis Inc. | $30 | Travel and Lodging | In-kind items and services | CABOMETYX Drug, Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | 2025 | |
| 2025-06-04 | Novartis Pharmaceuticals Corporation | $14 | Food and Beverage | In-kind items and services | KISQALI Drug, Oncology | 2025 | |
| 2025-06-03 | Exelixis Inc. | $4,620 | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | CABOMETYX Drug, Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | 2025 | |
| 2025-05-28 | Gilead Sciences, Inc. | $18 | Food and Beverage | In-kind items and services | Trodelvy Drug, ONC | 2025 | |
| 2025-05-19 | Karyopharm Therapeutics Inc. | $805 | Honoraria | Cash or cash equivalent | XPOVIO Drug, Oncology | 2025 | |
| 2025-05-18 | Incyte Corporation | $267 | Travel and Lodging | Cash or cash equivalent | Jakafi Drug, Hematology/Oncology | 2025 | |
| 2025-05-17 | Incyte Corporation | $1,091 | Travel and Lodging | Cash or cash equivalent | Jakafi Drug, Hematology/Oncology | 2025 | |
| 2025-05-17 | Incyte Corporation | $243 | Travel and Lodging | Cash or cash equivalent | Jakafi Drug, Hematology/Oncology | 2025 | |
| 2025-05-17 | Incyte Corporation | $53 | Food and Beverage | Cash or cash equivalent | Jakafi Drug, Hematology/Oncology | 2025 | |
| 2025-05-17 | Incyte Corporation | $20 | Food and Beverage | Cash or cash equivalent | Jakafi Drug, Hematology/Oncology | 2025 | |
| 2025-05-17 | Incyte Corporation | $20 | Food and Beverage | Cash or cash equivalent | Jakafi Drug, Hematology/Oncology | 2025 | |
| 2025-05-16 | Incyte Corporation | $405 | Travel and Lodging | Cash or cash equivalent | Jakafi Drug, Hematology/Oncology | 2025 | |
| 2025-05-15 | Exelixis Inc. | $1,168 | Travel and Lodging | In-kind items and services | CABOMETYX Drug, Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | 2025 | |
| 2025-05-15 | Incyte Corporation | $750 | Travel and Lodging | Cash or cash equivalent | Jakafi Drug, Hematology/Oncology | 2025 | |
| 2025-05-15 | Incyte Corporation | $598 | Travel and Lodging | Cash or cash equivalent | Jakafi Drug, Hematology/Oncology | 2025 | |
| 2025-05-15 | Incyte Corporation | $219 | Travel and Lodging | Cash or cash equivalent | Jakafi Drug, Hematology/Oncology | 2025 | |
| 2025-05-15 | Incyte Corporation | $182 | Travel and Lodging | Cash or cash equivalent | Jakafi Drug, Hematology/Oncology | 2025 | |
| 2025-05-15 | Genentech USA, Inc. | $13 | Food and Beverage | In-kind items and services | Tecentriq Biological, BioOncology | 2025 | |
| 2025-05-14 | Exelixis Inc. | $311 | Travel and Lodging | In-kind items and services | CABOMETYX Drug, Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | 2025 | |
| 2025-05-13 | AstraZeneca Pharmaceuticals LP | $6,030 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | DATROWAY Biological, Oncology | 2025 | |
| 2025-05-13 | Exelixis Inc. | $3,300 | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | CABOMETYX Drug, Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | 2025 | |
| 2025-05-13 | Incyte Corporation | $2,055 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Jakafi Drug, Hematology/Oncology | 2025 | |
| 2025-05-13 | Exelixis Inc. | $1,980 | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | CABOMETYX Drug, Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | 2025 | |
| 2025-05-13 | Exelixis Inc. | $70 | Travel and Lodging | In-kind items and services | CABOMETYX Drug, Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | 2025 | |
| 2025-05-13 | Exelixis Inc. | $30 | Travel and Lodging | In-kind items and services | CABOMETYX Drug, Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | 2025 | |
| 2025-05-12 | Exelixis Inc. | $443 | Travel and Lodging | In-kind items and services | CABOMETYX Drug, Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | 2025 | |
| 2025-05-12 | Exelixis Inc. | $370 | Travel and Lodging | In-kind items and services | CABOMETYX Drug, Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | 2025 | |
| 2025-05-07 | AstraZeneca Pharmaceuticals LP | $1,098 | Travel and Lodging | In-kind items and services | DATROWAY Biological, Oncology | 2025 | |
| 2025-05-07 | AstraZeneca Pharmaceuticals LP | $196 | Travel and Lodging | In-kind items and services | DATROWAY Biological, Oncology | 2025 | |
| 2025-05-07 | AstraZeneca Pharmaceuticals LP | $110 | Food and Beverage | In-kind items and services | DATROWAY Biological, Oncology | 2025 | |
| 2025-05-06 | AstraZeneca Pharmaceuticals LP | $6,030 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | DATROWAY Biological, Oncology | 2025 | |
| 2025-05-06 | Exelixis Inc. | $572 | Travel and Lodging | In-kind items and services | CABOMETYX Drug, Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | 2025 | |
| 2025-05-01 | AstraZeneca Pharmaceuticals LP | $1,357 | Travel and Lodging | In-kind items and services | LYNPARZA Drug, Oncology | 2025 | |
| 2025-05-01 | Exelixis Inc. | $698 | Travel and Lodging | In-kind items and services | CABOMETYX Drug, Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | 2025 | |
| 2025-05-01 | AstraZeneca Pharmaceuticals LP | $123 | Food and Beverage | In-kind items and services | LYNPARZA Drug, Oncology | 2025 | |
| 2025-05-01 | PFIZER INC. | $23 | Food and Beverage | In-kind items and services | INLYTA Drug, ONCOLOGY | 2025 | |
| 2025-04-29 | Incyte Corporation | $6,850 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Jakafi Drug, Hematology/Oncology | 2025 | |
| 2025-04-29 | Exelixis Inc. | $4,620 | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | CABOMETYX Drug, Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | 2025 | |
| 2025-04-29 | AstraZeneca Pharmaceuticals LP | $899 | Travel and Lodging | In-kind items and services | DATROWAY Biological, Oncology | 2025 | |
| 2025-04-29 | AstraZeneca Pharmaceuticals LP | $631 | Travel and Lodging | In-kind items and services | DATROWAY Biological, Oncology | 2025 | |
| 2025-04-29 | AstraZeneca Pharmaceuticals LP | $130 | Food and Beverage | In-kind items and services | DATROWAY Biological, Oncology | 2025 | |
| 2025-04-24 | Incyte Corporation | $692 | Travel and Lodging | Cash or cash equivalent | Jakafi Drug, Hematology/Oncology | 2025 | |
| 2025-04-24 | Incyte Corporation | $578 | Travel and Lodging | Cash or cash equivalent | Jakafi Drug, Hematology/Oncology | 2025 | |
| 2025-04-24 | Incyte Corporation | $296 | Travel and Lodging | Cash or cash equivalent | Jakafi Drug, Hematology/Oncology | 2025 | |
| 2025-04-24 | ABBVIE INC. | $28 | Food and Beverage | In-kind items and services | VENCLEXTA Drug, ONCOLOGY | 2025 | |
| 2025-04-22 | Exelixis Inc. | $70 | Travel and Lodging | In-kind items and services | CABOMETYX Drug, Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | 2025 | |
| 2025-04-17 | Exelixis Inc. | $802 | Travel and Lodging | In-kind items and services | CABOMETYX Drug, Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | 2025 | |
| 2025-04-17 | AstraZeneca Pharmaceuticals LP | $328 | Travel and Lodging | In-kind items and services | DATROWAY Biological, Oncology | 2025 | |
| 2025-04-17 | AstraZeneca Pharmaceuticals LP | $125 | Food and Beverage | In-kind items and services | DATROWAY Biological, Oncology | 2025 | |
| 2025-04-15 | AstraZeneca Pharmaceuticals LP | $6,030 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | DATROWAY Biological, Oncology | 2025 | |
| 2025-04-15 | AstraZeneca Pharmaceuticals LP | $6,030 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-04-10 | AstraZeneca Pharmaceuticals LP | $914 | Travel and Lodging | In-kind items and services | DATROWAY Biological, Oncology | 2025 | |
| 2025-04-10 | AstraZeneca Pharmaceuticals LP | $366 | Travel and Lodging | In-kind items and services | DATROWAY Biological, Oncology | 2025 | |
| 2025-04-10 | AstraZeneca Pharmaceuticals LP | $121 | Food and Beverage | In-kind items and services | DATROWAY Biological, Oncology | 2025 | |
| 2025-04-10 | Novartis Pharmaceuticals Corporation | $21 | Food and Beverage | In-kind items and services | Fabhalta Drug, Immunology | 2025 | |
| 2025-04-09 | Exelixis Inc. | $4,620 | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | CABOMETYX Drug, Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | 2025 | |
| 2025-04-09 | Exelixis Inc. | $4,620 | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | CABOMETYX Drug, Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | 2025 | |
| 2025-04-09 | Exelixis Inc. | $352 | Travel and Lodging | In-kind items and services | CABOMETYX Drug, Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | 2025 | |
| 2025-04-08 | Exelixis Inc. | $469 | Travel and Lodging | In-kind items and services | CABOMETYX Drug, Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | 2025 | |
| 2025-04-07 | Incyte Corporation | $342 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Jakafi Drug, Hematology/Oncology | 2025 | |
| 2025-04-07 | Karyopharm Therapeutics Inc. | $25 | Food and Beverage | In-kind items and services | XPOVIO Drug, Oncology | 2025 | |
| 2025-04-03 | AstraZeneca Pharmaceuticals LP | $802 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-04-03 | AstraZeneca Pharmaceuticals LP | $256 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-04-03 | Daiichi Sankyo Inc. | $20 | Food and Beverage | In-kind items and services | Enhertu Drug, ONCOLOGY | 2025 | |
| 2025-04-02 | Exelixis Inc. | $70 | Travel and Lodging | In-kind items and services | CABOMETYX Drug, Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | 2025 | |
| 2025-04-02 | Exelixis Inc. | $70 | Travel and Lodging | In-kind items and services | CABOMETYX Drug, Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | 2025 | |
| 2025-04-02 | Exelixis Inc. | $45 | Food and Beverage | In-kind items and services | CABOMETYX Drug, Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | 2025 |
The latest 200 records of 3,024.
Research payments naming this person as principal investigator
| Date | Company | Paid to | Amount | Study | Year |
|---|---|---|---|---|---|
| 2025-07-23 | Aadi Bioscience, Inc. | US Oncology Research | $1,446 | A Phase 2 Multi-center Open-label Basket Trial of Nab-sirolimus for Adult and Adolescent Patients With Malignant Solid T | 2025 |
| 2025-07-23 | Aadi Bioscience, Inc. | US Oncology Research | $1,750 | A Phase 2 Multi-center Open-label Basket Trial of Nab-sirolimus for Adult and Adolescent Patients With Malignant Solid T | 2025 |
| 2025-03-26 | Aadi Bioscience, Inc. | US Oncology Research | $2,438 | A Phase 2 Multi-center Open-label Basket Trial of Nab-sirolimus for Adult and Adolescent Patients With Malignant Solid T | 2025 |
| 2024-12-09 | Aadi Bioscience, Inc. | US Oncology Research | $1,125 | A Phase 2 Multi-center Open-label Basket Trial of Nab-sirolimus for Adult and Adolescent Patients With Malignant Solid T | 2024 |
| 2024-09-11 | Aadi Bioscience, Inc. | US Oncology Research | $1,125 | A Phase 2 Multi-center Open-label Basket Trial of Nab-sirolimus for Adult and Adolescent Patients With Malignant Solid T | 2024 |
| 2024-06-14 | Aadi Bioscience, Inc. | US Oncology Research | $1,125 | A Phase 2 Multi-center Open-label Basket Trial of Nab-sirolimus for Adult and Adolescent Patients With Malignant Solid T | 2024 |
| 2024-06-14 | Aadi Bioscience, Inc. | US Oncology Research | $15,500 | A Phase 2 Multi-center Open-label Basket Trial of Nab-sirolimus for Adult and Adolescent Patients With Malignant Solid T | 2024 |
| 2024-01-15 | Mirati Therapeutics, Inc. | Texas Onco Southwest Fort Worth | $16,252 | KRAS DetECT: KRAS mutation Detection to Evaluate Eligibility for Clinical Trials | 2024 |
| 2023-12-31 | Aadi Bioscience, Inc. | Texas Oncology - McAllen | $184,427 | Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/_TSC2 | 2023 |
| 2023-10-15 | Mirati Therapeutics, Inc. | Texas Oncology PA | $956 | MA-MRTX100 DeTECT Study | 2023 |
| 2023-07-15 | Mirati Therapeutics, Inc. | Texas Oncology PA | $956 | MA-MRTX100 DeTECT Study | 2023 |
| 2023-04-15 | Mirati Therapeutics, Inc. | Texas Oncology PA | $190 | MA-MRTX100 DeTECT Study | 2023 |
| 2023-04-15 | Mirati Therapeutics, Inc. | Texas Oncology PA | $92 | MA-MRTX100 DeTECT Study | 2023 |
| 2023-04-15 | Mirati Therapeutics, Inc. | Texas Oncology PA | $956 | MA-MRTX100 DeTECT Study | 2023 |
| 2023-03-15 | Mirati Therapeutics, Inc. | Texas Oncology PA | $190 | MA-MRTX100 DeTECT Study | 2023 |
| 2023-03-15 | Mirati Therapeutics, Inc. | Texas Oncology PA | $265 | MA-MRTX100 DeTECT Study | 2023 |
| 2023-03-15 | Mirati Therapeutics, Inc. | Texas Oncology PA | $780 | MA-MRTX100 DeTECT Study | 2023 |
| 2023-03-15 | Mirati Therapeutics, Inc. | Texas Oncology PA | $92 | MA-MRTX100 DeTECT Study | 2023 |
| 2023-01-26 | Mirati Therapeutics, Inc. | MEMORIAL SLOAN-KETTERING CENTER | $1,125 | KRAS DetECT: KRAS mutation Detection to Evaluate Eligibility for Clinical Trials | 2023 |
| 2023-01-15 | Mirati Therapeutics, Inc. | Texas Oncology PA | $780 | MA-MRTX100 DeTECT Study | 2023 |
| 2023-01-15 | AstraZeneca Pharmaceuticals LP | TEXAS ONCOLOGY SOUTHWEST FORT WORTH | $5,064 | A Retrospective Analysis of Biomarker Testing Variance and Treatment Patterns among Patients with Metastatic Non-Small C | 2023 |
| 2023-01-15 | Mirati Therapeutics, Inc. | Texas Oncology PA | $265 | MA-MRTX100 DeTECT Study | 2023 |
| 2023-01-15 | Mirati Therapeutics, Inc. | Texas Oncology PA | $956 | MA-MRTX100 DeTECT Study | 2023 |
| 2022-04-27 | SEAGEN INC. | Texas Oncology - McAllen | $15,277 | A Phase II, Open Label Study of Tucatinib Combined With Trastuzumab in Patients With HER2+ Metastatic Colorectal Cancer | 2022 |
| 2022-04-15 | SEAGEN INC. | Texas Oncology - McAllen | $175 | A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Ab | 2022 |
| 2022-04-15 | SEAGEN INC. | Texas Oncology - McAllen | $175 | A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Ab | 2022 |
| 2022-04-15 | SEAGEN INC. | Texas Oncology - McAllen | $151 | A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Ab | 2022 |
| 2022-04-15 | SEAGEN INC. | Texas Oncology - McAllen | $425 | Screening protocol to detect HER2 alterations required for enrollment on clinical research protocols of tucatinib | 2022 |
| 2022-04-15 | SEAGEN INC. | Texas Oncology - McAllen | $956 | A Phase II, Open Label Study of Tucatinib Combined With Trastuzumab in Patients With HER2+ Metastatic Colorectal Cancer | 2022 |
| 2022-01-15 | SEAGEN INC. | Texas Oncology - McAllen | $425 | Screening protocol to detect HER2 alterations required for enrollment on clinical research protocols of tucatinib | 2022 |
| 2022-01-15 | SEAGEN INC. | Texas Oncology - McAllen | $956 | A Phase II, Open Label Study of Tucatinib Combined With Trastuzumab in Patients With HER2+ Metastatic Colorectal Cancer | 2022 |
| 2021-12-15 | SEAGEN INC. | Texas Oncology - McAllen | $821 | A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Ab | 2021 |
| 2021-11-15 | SEAGEN INC. | Texas Oncology - McAllen | $855 | A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Ab | 2021 |
| 2021-11-15 | SEAGEN INC. | Texas Oncology - McAllen | $855 | A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Ab | 2021 |
| 2021-10-15 | SEAGEN INC. | Texas Oncology - McAllen | $425 | Screening protocol to detect HER2 alterations required for enrollment on clinical research protocols of tucatinib | 2021 |
| 2021-10-15 | SEAGEN INC. | Texas Oncology - McAllen | $855 | A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Ab | 2021 |
| 2021-10-15 | SEAGEN INC. | Texas Oncology - McAllen | $956 | A Phase II, Open Label Study of Tucatinib Combined With Trastuzumab in Patients With HER2+ Metastatic Colorectal Cancer | 2021 |
| 2021-10-15 | SEAGEN INC. | Texas Oncology - McAllen | $260 | A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Ab | 2021 |
| 2021-10-15 | SEAGEN INC. | Texas Oncology - McAllen | $480 | A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Ab | 2021 |
| 2021-10-15 | SEAGEN INC. | Texas Oncology - McAllen | $25 | A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Ab | 2021 |
| 2021-10-15 | SEAGEN INC. | Texas Oncology - McAllen | $930 | A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Ab | 2021 |
| 2021-10-15 | SEAGEN INC. | Texas Oncology - McAllen | $25 | A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Ab | 2021 |
| 2021-09-15 | SEAGEN INC. | Texas Oncology - McAllen | $1,020 | A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Ab | 2021 |
| 2021-09-15 | SEAGEN INC. | Texas Oncology - McAllen | $1,020 | A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Ab | 2021 |
| 2021-09-15 | SEAGEN INC. | Texas Oncology - McAllen | $2,720 | A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Ab | 2021 |
| 2021-09-15 | SEAGEN INC. | Texas Oncology - McAllen | $175 | A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Ab | 2021 |
| 2021-09-15 | SEAGEN INC. | Texas Oncology - McAllen | $1,020 | A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Ab | 2021 |
| 2021-08-15 | SEAGEN INC. | Texas Oncology - McAllen | $856 | A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Ab | 2021 |
| 2021-08-15 | SEAGEN INC. | Texas Oncology - McAllen | $2,720 | A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Ab | 2021 |
| 2021-08-15 | SEAGEN INC. | Texas Oncology - McAllen | $856 | A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Ab | 2021 |
| 2021-07-15 | SEAGEN INC. | Texas Oncology - McAllen | $175 | A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Ab | 2021 |
| 2021-07-15 | SEAGEN INC. | Texas Oncology - McAllen | $1,006 | A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Ab | 2021 |
| 2021-07-15 | SEAGEN INC. | Texas Oncology - McAllen | $931 | A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Ab | 2021 |
| 2021-07-15 | SEAGEN INC. | Texas Oncology - McAllen | $425 | Screening protocol to detect HER2 alterations required for enrollment on clinical research protocols of tucatinib | 2021 |
| 2021-07-15 | SEAGEN INC. | Texas Oncology - McAllen | $956 | A Phase II, Open Label Study of Tucatinib Combined With Trastuzumab in Patients With HER2+ Metastatic Colorectal Cancer | 2021 |
| 2021-06-15 | SEAGEN INC. | Texas Oncology - McAllen | $1,080 | A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Ab | 2021 |
| 2021-04-15 | SEAGEN INC. | Texas Oncology - McAllen | $425 | Screening protocol to detect HER2 alterations required for enrollment on clinical research protocols of tucatinib | 2021 |
| 2021-04-15 | SEAGEN INC. | Texas Oncology - McAllen | $956 | A Phase II, Open Label Study of Tucatinib Combined With Trastuzumab in Patients With HER2+ Metastatic Colorectal Cancer | 2021 |
| 2021-04-15 | SEAGEN INC. | Texas Oncology - McAllen | $1,020 | A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Ab | 2021 |
| 2021-04-15 | SEAGEN INC. | Texas Oncology - McAllen | $1,281 | A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Ab | 2021 |
| 2021-03-15 | SEAGEN INC. | Texas Oncology - McAllen | $1,350 | A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Ab | 2021 |
| 2021-03-15 | SEAGEN INC. | Texas Oncology - McAllen | $1,315 | Screening protocol to detect HER2 alterations required for enrollment on clinical research protocols of tucatinib | 2021 |
| 2021-03-15 | SEAGEN INC. | Texas Oncology - McAllen | $2,620 | A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Ab | 2021 |
| 2021-02-15 | SEAGEN INC. | Texas Oncology - McAllen | $450 | A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Ab | 2021 |
| 2021-01-15 | SEAGEN INC. | Texas Oncology - McAllen | $956 | A Phase II, Open Label Study of Tucatinib Combined With Trastuzumab in Patients With HER2+ Metastatic Colorectal Cancer | 2021 |
| 2020-11-02 | Secura Bio, Inc. | Texas Oncology, P.A. | $14,175 | VS-0145-225 | 2020 |
| 2020-07-14 | Verastem, Inc. | TEXAS ONCOLOGY MCALLEN | $1 | VS-0145-225 | 2020 |
| 2020-07-14 | Verastem, Inc. | TEXAS ONCOLOGY MCALLEN | $22 | VS-0145-225 | 2020 |
| 2020-07-14 | Verastem, Inc. | TEXAS ONCOLOGY MCALLEN | $1 | VS-0145-225 | 2020 |
| 2020-07-14 | Verastem, Inc. | TEXAS ONCOLOGY MCALLEN | $41 | VS-0145-225 | 2020 |
| 2020-07-14 | Verastem, Inc. | TEXAS ONCOLOGY MCALLEN | $205 | VS-0145-225 | 2020 |
| 2020-07-14 | Verastem, Inc. | TEXAS ONCOLOGY MCALLEN | $5 | VS-0145-225 | 2020 |
| 2020-07-14 | Verastem, Inc. | TEXAS ONCOLOGY MCALLEN | $2 | VS-0145-225 | 2020 |
| 2020-07-14 | Verastem, Inc. | TEXAS ONCOLOGY MCALLEN | $11 | VS-0145-225 | 2020 |
| 2020-07-14 | Verastem, Inc. | TEXAS ONCOLOGY MCALLEN | $0 | VS-0145-225 | 2020 |
| 2019-03-06 | Boehringer Ingelheim Pharmaceuticals, Inc. | SAGACT PLLC | $15,342 | Phase 2 longterm Open Label Extension Study in UC | 2019 |
| 2019-01-21 | Boehringer Ingelheim Pharmaceuticals, Inc. | SAGACT PLLC | $1,789 | Phase II III in UC patients | 2019 |
| 2019-01-04 | Boehringer Ingelheim Pharmaceuticals, Inc. | SAGACT PLLC | $10,001 | Phase II III in UC patients | 2019 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In McAllen, TX, county Hidalgo County, TX, state Texas; placed by its city name.
| Measure | Place (city or town) McAllen, TX | County Hidalgo County, TX | State Texas |
|---|---|---|---|
| Population B01003 | 145,385 | 891,977 | 30,188,424 |
| Population, 2020 census P1 | 142,210 | 870,781 | 29,145,505 |
| Median age B01002 | 33.5 | 30.5 | 35.6 |
| Under 18 B01001 | 28.2% | 31.0% | 25.0% |
| 65 and over B01001 | 13.1% | 11.7% | 13.4% |
| Households B11001 | 48,905 | 270,210 | 10,992,816 |
| Foreign born B05002 | 26.2% | 26.1% | 17.6% |
| Median household income B19013 | $61,579 | $54,338 | $78,476 |
| Median family income B19113 | $69,052 | $60,128 | $94,599 |
| Per capita income B19301 | $30,885 | $23,117 | $40,752 |
| Poverty rate B17001 | 20.0% | 26.7% | 13.8% |
| Unemployment rate B23025 | 6.0% | 7.6% | 5.3% |
| Civilian labor force B23025 | 67,484 | 382,422 | 15,233,563 |
| Mean commute (minutes) B08013 | 21.9 | 22.5 | 26.7 |
| Bachelor's degree or higher B15003 | 32.5% | 20.6% | 33.8% |
| Housing units B25001 | 55,385 | 308,556 | 12,128,515 |
| Owner-occupied B25003 | 59.5% | 67.5% | 62.6% |
| Renters B25003 | 40.5% | 32.5% | 37.4% |
| Median home value B25077 | $190,400 | $140,900 | $283,800 |
| Median gross rent B25064 | $1,049 | $957 | $1,403 |
| White, not Hispanic B03002 | 8.5% | 6.0% | 39.1% |
| Black B03002 | 0.6% | 0.6% | 11.9% |
| Hispanic or Latino B03002 | 87.0% | 91.9% | 39.7% |
| Asian B03002 | 2.7% | 1.0% | 5.5% |
| American Indian and Alaska Native B03002 | 0.2% | 0.1% | 0.1% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in McAllen, TX.
Comments